diltiazem has been researched along with troleandomycin in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dansette, PM; Fontana, E; Poli, SM | 1 |
Pratim Roy, P; Roy, K | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Kohno, Y; Suzuki, A; Yamamoto, T | 1 |
Hall, K; Meredith, S; Murray, KT; Narasimhulu, SS; Ray, WA; Stein, CM | 1 |
Chen, Y; Fretland, AJ; Liu, L; Monshouwer, M | 1 |
1 review(s) available for diltiazem and troleandomycin
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
7 other study(ies) available for diltiazem and troleandomycin
Article | Year |
---|---|
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method.
Topics: Amiodarone; Animals; Baculoviridae; Binding, Competitive; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Enzyme Inhibitors; Fluorescence; Humans; Inhibitory Concentration 50; Ketoconazole; Miconazole; Midazolam; Propafenone; Quinolines; Recombinant Proteins; Troleandomycin; Verapamil | 2004 |
Oral erythromycin and the risk of sudden death from cardiac causes.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Confounding Factors, Epidemiologic; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Diltiazem; Drug Interactions; Erythromycin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Nitroimidazoles; Oxidoreductases, N-Demethylating; Risk; Troleandomycin; Verapamil | 2004 |
Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
Topics: Cryopreservation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Erythromycin; Hepatocytes; Humans; Microsomes, Liver; Pharmacokinetics; Risk Assessment; Time Factors; Troleandomycin; Verapamil | 2011 |